GlassScriptPhysician profile
Saffron Ruth Hackett
NPI 1730728940
$2,784.85
in general payments reported to CMS, 2019-2025
19 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $704 · 2022: $1,443 · 2023: $237 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.58 | 2021-2023 | |
| Lilly USA, LLC | $410.52 | 2021-2023 | Taltz, Olumiant |
| Janssen Biotech, INC. | $402.02 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $348.14 | 2021-2022 | |
| Genzyme Corporation | $237.95 | 2021-2025 | |
| Ucb, INC. | $138.65 | 2021-2025 | |
| Allergan, INC. | $130.38 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.31 | 2021 | |
| Leo Pharma INC. | $78.57 | 2022-2025 | Anzupgo |
| Regeneron Healthcare Solutions, INC. | $75.45 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $71.66 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $60.53 | 2021-2022 | |
| Incyte Corporation | $49.68 | 2022-2023 | Opzelura |
| Pfizer INC. | $39.83 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $24.44 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.64 | 2022 | |
| Sumitomo Pharma America, INC. | $18.94 | 2023 | Myfembree |
| Emd Serono, INC. | $15.38 | 2023 | |
| Organon LLC | $12.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saffron Hackett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.